CT-guided percutaneous radiofrequency ablation for lung neoplasms adjacent to the pericardium. (August 2018)

• Record Type: Journal Article
• Authors: Mu, Luwen; Pan, Tao; Lyu, Ning; Sun, Lin; Li, Shaolong; Xie, Qiankun; Deng, Haijing; Wu, Peihong; Liu, Hui; Zhao, Ming
• Is Part Of: Lung cancer. Volume 122(2018)
• Page Start: 25
• Page End: 31
• Publication Date: 2018-08
• Subjects: CT computed tomography -- LPFS local progression free survival -- RFA radiofrequency ablation -- SBRT stereotactic body radiation therapy -- VATS video-assisted thoracic surgery; Radiofrequency ablation -- Lung malignancies -- Pericardium -- Complications -- Local progression-free survival; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2018.05.004
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: The success rate of RFA was 96.1%. L-PFS was 93.0%, 84.0%, and 77.0% at 6, 12, and 24 months, respectively. The incidence of major complications was 15.7%. Patients experienced an increase in the heart rate and blood pressure. Abstract: Objective: To assess the safety and effectiveness of computed-tomography-guided (CT-guided) percutaneous radiofrequency ablation (RFA) for lung neoplasms adjacent to the pericardium. Materials and methods: This retrospective study was approved by the institutional ethics committee, and all patients provided written informed consent. Between January 1, 2012 and March 31, 2016, 49 consecutive patients (32 men and 17 women; mean age 47.9 years; range 16–67 years) with 51 tumors (mean diameter 17.7 ± 7.2 mm; range 4–30 mm) located within 10 mm of the pericardium underwent percutaneous CT-guided RFA. The technical success rate, local progression-free survival (LPFS), risk factors for local progression, and safety of this technique were evaluated. Results: The technical success rate was 96.1% (49/51), and the LPFS was 98.0%, 93.0%, 84.0%, and 77.0% at 3, 6, 12, and 24 months, respectively. A tumor size >2.0 cm (p = .045) and the primary lung tumor types (p = .013) were associated with local progression. No treatment-related deaths occurred. The incidence of major complications was 15.7%; complications included pneumothorax (5.9%, 3/51), pleural effusion (3.9%, 2/51), pneumonitis (3.9%, 2/51), and hemothorax (2.0%, 1/51). Conclusion: Percutaneous CT-guided RFA can be a safe and effective option for the treatment of lung malignancies adjacent to the pericardium.